IMNM Stock Price, Immunome Inc Quote, Chart

Market Summary

USD14.96+0.27

Market Closed

1.84%

IMNM Stock Price

View Fullscreen

IMNM RSI Chart

IMNM Valuation

Market Cap

893.0M

Price/Earnings (Trailing)

-8.36

Price/Sales (Trailing)

63.71

Price/Free Cashflow

-106.33

IMNM Price/Sales (Trailing)

IMNM Profitability

Return on Equity

-89.09%

Return on Assets

-71.9%

Free Cashflow Yield

-0.94%

IMNM Fundamentals

IMNM Revenue

Revenue (TTM)

14.0M

Rev. Growth (Yr)

156.26%

Rev. Growth (Qtr)

7.32%

IMNM Earnings

Earnings (TTM)

-106.8M

Earnings Growth (Yr)

-1.1K%

Earnings Growth (Qtr)

-2.0K%

Breaking Down IMNM Revenue

Last 7 days

4.9%

Last 30 days

-30.1%

Last 90 days

-8.2%

Trailing 12 Months

193.9%

How does IMNM drawdown profile look like?

IMNM Financial Health

Current Ratio

6.63

IMNM Investor Care

Shares Dilution (1Y)

389.53%

Diluted EPS (TTM)

-5.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0M	7.3M	10.7M	14.0M
2022	0	0	0	622.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Immunome Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 02, 2023	turner bruce	bought	249,993	5.91	42,300	chief strategy officer
Oct 02, 2023	prendergast franklyn g	acquired	-	-	60,840	-
Oct 02, 2023	siegall clay b	bought	999,996	5.91	169,204	president and ceo
Oct 02, 2023	rapp michael	acquired	1,499,990	5.91	253,806	-
Jan 15, 2023	lefenfeld michael	acquired	55,500	4.00	13,875	-
Jan 15, 2023	rapp michael	acquired	70,000	4.00	17,500	-
Jan 15, 2023	wagenheim philip	acquired	35,000	4.00	8,750	-
Jan 15, 2023	lamattina john l	acquired	60,500	4.00	15,125	-
Sep 13, 2021	rapp michael	bought	518,202	19.96	25,962	-
Sep 10, 2021	rapp michael	bought	276,675	17.85	15,500	-

Which funds bought or sold IMNM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Sterling Investment Advisors, Ltd.	reduced	-26.53	126,110	307,636	0.09%
May 01, 2024	CAPSTONE INVESTMENT ADVISORS, LLC	new	-	1,043,960	1,043,960	-%
Apr 26, 2024	Clear Creek Financial Management, LLC	new	-	546,736	546,736	0.07%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	16.49	49,000	78,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-169,531	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-2,408	-	-%
Apr 24, 2024	BROWN ADVISORY INC	new	-	16,529,700	16,529,700	0.02%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-15.75	131,220	270,320	-%
Mar 11, 2024	VANGUARD GROUP INC	added	339	15,308,900	18,618,300	-%

Are Funds Buying or Selling IMNM?

Are funds buying IMNM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMNM

No. of Funds

Unveiling Immunome Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	alpine global management, llc	0.45%	192,333	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Oct 12, 2023	ecor1 capital, llc	9.1%	3,879,415	SC 13G
Oct 12, 2023	barchas isaac	3.4%	-	SC 13D
Oct 12, 2023	immunome aggregator, lp	8.1%	0	SC 13D
Oct 12, 2023	redmile group, llc	9.1%	3,879,415	SC 13G
Jul 07, 2023	morphimmune inc.	20%	2,659,508	SC 13D
Feb 14, 2023	prentice capital management, lp	4.11%	498,145	SC 13G/A
Jan 17, 2023	alpine global management, llc	5.9%	718,235	SC 13G/A
Feb 14, 2022	rapp michael	9.6%	1,181,575	SC 13G/A

Recent SEC filings of Immunome Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	3	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 03, 2024	S-3ASR	S-3ASR
Apr 03, 2024	S-3ASR	S-3ASR
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to Immunome Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Immunome Inc News

Latest updates

Immunome Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q3
Revenue	7.3%	3,826	3,565	4,263	2,364	1,493	622	-
Operating Expenses	1101.3%	98,479	8,198	10,036	6,835	7,787	8,534	-
S&GA Expenses	83.8%	8,040	4,375	4,320	2,922	3,535	3,309	-
R&D Expenses	152.1%	9,637	3,823	5,716	3,913	4,252	5,225	-
Interest Expenses	601.0%	2,019	288	216	201	1.00	1.00	-
Net Income	-2032.0%	-92,634	-4,345	-5,557	-4,270	-7,786	-8,533	-
Net Income Margin	-270.2%	-7.62*	-2.06*	-3.57*	-7.43*	-59.32*	-	-
Free Cashflow	-105.9%	-17,808	-8,650	-6,008	24,067	-6,755	-7,571	-8,230

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	59.4%	149	93.00	41.00	48.00	24.00	31.00	39.00	48.00	58.00	63.00	64.00	43.00	45.00	12.00	5.00
Current Assets	58.3%	145	91.00	40.00	47.00	23.00	29.00	38.00	46.00	57.00	61.00	63.00	41.00	43.00	7.00	3.00
Cash Equivalents	8.9%	99.00	91.00	38.00	44.00	20.00	27.00	35.00	43.00	49.00	56.00	60.00	36.00	40.00	7.00	3.00
Net PPE	76.9%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Liabilities	-67.1%	29.00	87.00	32.00	34.00	7.00	7.00	9.00	10.00	10.00	8.00	4.00	5.00	3.00	13.00	2.00
Current Liabilities	-5.5%	22.00	23.00	26.00	25.00	7.00	7.00	9.00	10.00	10.00	8.00	4.00	5.00	3.00	5.00	2.00
Shareholder's Equity	1873.0%	120	6.00	9.00	14.00	17.00	23.00	30.00	38.00	48.00	55.00	61.00	38.00	41.00	-	-
Retained Earnings	-71.1%	-222	-130	-125	-120	-116	-108	-99.68	-90.76	-79.10	-71.30	-63.50	-58.29	-54.39	-50.32	-36.60
Additional Paid-In Capital	151.5%	343	136	135	134	133	131	130	129	127	126	124	96.00	96.00	1.00	1.00
Shares Outstanding	254.4%	43.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	11.00	11.00	11.00	11.00	-	-
Float	-	-	-	76.00	-	-	-	34.00	-	-	-	182	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-102.7%	-17,459	-8,614	-5,668	24,173	-6,683	-7,571	-8,060	-6,376	-6,805	-4,145	-3,741	-3,535	-6,062	-2,528	-1,480	-2,064	-	-
Share Based Compensation	166.2%	2,883	1,083	1,033	1,224	1,355	1,340	1,327	1,310	1,219	1,155	749	325	319	117	39.00	146	-	-
Cashflow From Investing	-83238.9%	-30,002	-36.00	-340	-106	-72.00	-	-170	-6.00	-14.00	-26.00	-8.00	-31.00	-46.00	-124	-361	-55.00	-	-
Cashflow From Financing	-8.8%	55,499	60,875	-	34.00	-	-	-	32.00	-195	585	27,302	76.00	39,130	-393	10,362	844	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IMNM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
	Sep. 02, 2022	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations and Comprehensive Loss
Collaboration revenue		$ 14,018
Operating expenses:
In-process research and development		80,802
Research and development		23,089	$ 23,272
General and administrative		19,657	13,629
Total operating expenses		123,548	36,901
Loss from operations		(109,530)	(36,901)
Interest income		2,724	5
Net loss		(106,806)	(36,896)
Deemed dividend arising from warrant modification	$ (600)		(622)
Net loss attributable to common stockholders		$ (106,806)	$ (37,518)
Per share information:
Net loss per common share, Basic		$ (5.38)	$ (3.09)
Net loss per common share, Diluted		$ (5.38)	$ (3.09)
Weighted-average common shares outstanding, Basic		19,843,651	12,126,573
Weighted-average common shares outstanding, Diluted		19,843,651	12,126,573
Comprehensive loss
Net loss		$ (106,806)	$ (37,518)
Unrealized gain on marketable securities		22
Comprehensive loss		$ (106,784)	$ (37,518)

IMNM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 98,679	$ 20,323
Marketable securities	39,463
Prepaid expenses and other current assets	6,561	2,326
Total current assets	144,703	22,649
Property and equipment, net	2,073	681
Operating right-of-use asset, net	1,564	284
Restricted cash	100	100
Deferred offering costs		332
Other long-term assets	100
Total assets	148,540	24,046
Current liabilities:
Accounts payable	3,311	2,400
Accrued expenses and other current liabilities	8,025	4,931
Deferred revenue, current	10,493
Total current liabilities	21,829	7,331
Deferred revenue, non-current	5,489
Other long-term liabilities	1,340	62
Total liabilities	28,658	7,393
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2023 and 2022
Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,251,778 shares issued and outstanding at December 31, 2023 and 12,128,843 shares issued and outstanding at December 31, 2022	4	1
Additional paid-in capital	342,663	132,653
Accumulated other comprehensive income	22
Accumulated deficit	(222,807)	(116,001)
Total stockholders' equity	119,882	16,653
Total liabilities and stockholders' equity	$ 148,540	$ 24,046

About Immunome Inc

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

CEO	Dr. Purnanand Duddu Sarma Ph.D.
WEBSITE	https://immunome.com
INDUSTRY	Biotechnology
EMPLOYEES	37

Immunome Inc Frequently Asked Questions

What is the ticker symbol for Immunome Inc? What does IMNM stand for in stocks?

IMNM is the stock ticker symbol of Immunome Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunome Inc (IMNM)?

As of Thu May 02 2024, market cap of Immunome Inc is 893.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMNM stock?

You can check IMNM's fair value in chart for subscribers.

What is the fair value of IMNM stock?

You can check IMNM's fair value in chart for subscribers. The fair value of Immunome Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immunome Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMNM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immunome Inc a good stock to buy?

The fair value guage provides a quick view whether IMNM is over valued or under valued. Whether Immunome Inc is cheap or expensive depends on the assumptions which impact Immunome Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMNM.

What is Immunome Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, IMNM's PE ratio (Price to Earnings) is -8.36 and Price to Sales (PS) ratio is 63.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMNM PE ratio will change depending on the future growth rate expectations of investors.